Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (31-40 of 466) with videos related to

Pageof 47
Sort By:
Hematology. American Society of Hematology. Education Program|December 7, 2024
Risk-stratification in frontline CLL therapy: standard of careEugen Tausch, Christof Schneider, Stephan Stilgenbauer
F1000Prime Reports|August 29, 2014
Advances in treating chronic lymphocytic leukemiaEugen Tausch, Daniel Mertens, Stephan Stilgenbauer
Blood|October 27, 2019
Response: Or both?Göran Roos, Richard Rosenquist, Stephan Stilgenbauer
Oncotarget|July 2, 2019
Targeted therapy in CLL: changing the treatment paradigmChristof Schneider, Daniela Steinbrecher, Stephan Stilgenbauer
Expert Opinion on Pharmacotherapy|November 22, 2011
Treating chronic lymphocytic leukemia with thalidomide and lenalidomideKrzysztof Giannopoulos, Daniel Mertens, Stephan Stilgenbauer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Immunoglobulin heavy chain variable gene usage and (super)-antigen drive in chronic lymphocytic leukemiaAndreas Bühler, Thorsten Zenz, Stephan Stilgenbauer
Haematologica|September 3, 2010
Biological diversity and risk-adapted treatment of chronic lymphocytic leukemiaThorsten Zenz, Daniel Mertens, Stephan Stilgenbauer
Blood Cancer Discovery|December 12, 2025
Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβBilly Michael Chelliah Jebaraj, Stephan Stilgenbauer
Leukemia & Lymphoma|December 17, 2009
More (on) prognostic factors in chronic lymphocytic leukemiaThorsten Zenz, Simone Fulda, Stephan Stilgenbauer
Blood|January 1, 2026
Shifting clones: CLL evolution under pirtobrutinib treatmentBilly Michael Chelliah Jebaraj, Stephan Stilgenbauer
Pageof 47

Showing results (31-40 of 466) with videos related to

Sort By:
Pageof 47
Hematology. American Society of Hematology. Education Program|December 7, 2024
Risk-stratification in frontline CLL therapy: standard of careEugen Tausch, Christof Schneider, Stephan Stilgenbauer
F1000Prime Reports|August 29, 2014
Advances in treating chronic lymphocytic leukemiaEugen Tausch, Daniel Mertens, Stephan Stilgenbauer
Blood|October 27, 2019
Response: Or both?Göran Roos, Richard Rosenquist, Stephan Stilgenbauer
Oncotarget|July 2, 2019
Targeted therapy in CLL: changing the treatment paradigmChristof Schneider, Daniela Steinbrecher, Stephan Stilgenbauer
Expert Opinion on Pharmacotherapy|November 22, 2011
Treating chronic lymphocytic leukemia with thalidomide and lenalidomideKrzysztof Giannopoulos, Daniel Mertens, Stephan Stilgenbauer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Immunoglobulin heavy chain variable gene usage and (super)-antigen drive in chronic lymphocytic leukemiaAndreas Bühler, Thorsten Zenz, Stephan Stilgenbauer
Haematologica|September 3, 2010
Biological diversity and risk-adapted treatment of chronic lymphocytic leukemiaThorsten Zenz, Daniel Mertens, Stephan Stilgenbauer
Blood Cancer Discovery|December 12, 2025
Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβBilly Michael Chelliah Jebaraj, Stephan Stilgenbauer
Leukemia & Lymphoma|December 17, 2009
More (on) prognostic factors in chronic lymphocytic leukemiaThorsten Zenz, Simone Fulda, Stephan Stilgenbauer
Blood|January 1, 2026
Shifting clones: CLL evolution under pirtobrutinib treatmentBilly Michael Chelliah Jebaraj, Stephan Stilgenbauer
Pageof 47